On Monday, Cognition Therapeutics Inc (NASDAQ: CGTX) opened lower -4.84% from the last session, before settling in for the closing price of $0.43. Price fluctuations for CGTX have ranged from $0.34 to $2.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 2.96% at the time writing. With a float of $33.80 million, this company’s outstanding shares have now reached $40.13 million.
The extent of productivity of a business whose workforce counts for 28 workers is very important to gauge. In terms of profitability, gross margin is 48.66%, operating margin of -15707.53%, and the pretax margin is -9212.37%.
Cognition Therapeutics Inc (CGTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cognition Therapeutics Inc is 15.78%, while institutional ownership is 10.72%. The most recent insider transaction that took place on Mar 14 ’24, was worth 9,975. In this transaction CEO & President of this company bought 5,700 shares at a rate of $1.75, taking the stock ownership to the 291,345 shares.
Cognition Therapeutics Inc (CGTX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.27 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.32) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.96% per share during the next fiscal year.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Check out the current performance indicators for Cognition Therapeutics Inc (CGTX). In the past quarter, the stock posted a quick ratio of 2.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
The latest stats from [Cognition Therapeutics Inc, CGTX] show that its last 5-days average volume of 9.81 million was superior to 0.7 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 9.06%. Additionally, its Average True Range was 0.05.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 3.05%, which indicates a significant decrease from 12.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.78% in the past 14 days, which was lower than the 139.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4827, while its 200-day Moving Average is $1.3737. Now, the first resistance to watch is $0.4651. This is followed by the second major resistance level at $0.5233. The third major resistance level sits at $0.5674. If the price goes on to break the first support level at $0.3628, it is likely to go to the next support level at $0.3187. Assuming the price breaks the second support level, the third support level stands at $0.2605.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
There are currently 41,548K shares outstanding in the company with a market cap of 16.91 million. Presently, the company’s annual sales total 0 K according to its annual income of -25,790 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -9,940 K.
